COVID-19
- CAPCaT Fast-Track Program for SARS-CoV-2 Test Development
- UMMS Update as of June 1, 2020
- NIH Update as of June 1, 2020
- COVID-19 Clinical Trials Database
- BARDA Funding Opportunities
- The National COVID Cohort Collaborative (N3C)

IN THE SPOTLIGHT
- FREE CAPCaT Virtual Startup Showcase & Strategic Partnership Connector

FUNDING
- CCTS SPARK Program (Small Pilot and Research Knowledge)
- CTS Small Conference Grants
- T32PRACCTIS Program

EDUCATION
- UMass Amherst Survey: Clinician Input Needed
- Patient-facing survey: What’s your take on new medical technology?

DID YOU KNOW
- HRPP QA/QI
- National Center for Data to Health (CD2H)

COVID - 19

UMASS CAPCaT TEAM LEADING EFFORT FOR COVID-19 TEST DEVELOPMENT AND DISTRIBUTION: The NIH is urgently soliciting proposals and can provide up to $500M across multiple projects to rapidly produce innovative SARS-CoV-2 diagnostic tests that will assist the public’s safe return to normal activities. Rapid Acceleration of Diagnostics (RADx) is a fast-track technology development program that will support novel solutions that build the U.S. capacity for testing up to 100-fold above what is achievable with standard approaches. RADx is structured to deliver innovative testing strategies to the public as soon as late summer 2020 and is an accelerated and comprehensive multi-pronged effort by NIH to make SARS-CoV-2 testing readily available to every American.
The application portal is now live [www.poctrn.org/radx](http://www.poctrn.org/radx). For more information: [https://www.youtube.com/watch?v=ofAldSGoZOg](https://www.youtube.com/watch?v=ofAldSGoZOg)

**UMMS UPDATE** regarding human subjects research during the COVID-19 pandemic can be found here: [https://umassmed.edu/ccts/covid-19/](https://umassmed.edu/ccts/covid-19/). This website is updated frequently.

**NIH UPDATE**: For up-to-date NIH COVID-19 information, including informational videos, proposal submission and award management resources, human subjects and clinical trials guidance, animal welfare, frequently asked questions regarding flexibilities for grantees, and funding opportunities, click [here](https://www.nih.gov/health-information/coronavirus) or copy and paste this url: [https://www.nih.gov/health-information/coronavirus](https://www.nih.gov/health-information/coronavirus)

**CLINICAL TRIALS DATABASE**: To search for active Covid-19 clinical trials, click [here](https://www.nih.gov/health-information/coronavirus).

**BARDA FUNDING OPPORTUNITIES (for coronavirus researchers)**: To support ongoing U.S. Government COVID-19 medical countermeasure development efforts, BARDA is pleased to open their EZ BAA program and seeks abstract submissions for the following critical areas of interest: (1) AOI #4.1-A: Molecular Diagnostic Assay for SARS-CoV-2 virus on existing FDA-cleared platform; (2) AOI #4.1-B: Point-of-Care Diagnostic Assay for detection of SARS-CoV-2 virus; (3) AOI #4.1-C: Diagnostic Assay for detection of COVID-19 disease; (4) AOI #4.3: COVID-19 Vaccine; and (5) AOI #4.4: Advanced Manufacturing Technologies. Please see the updated solicitation [BAA-20-100-SOL-0002](https://www.nih.gov/health-information/coronavirus) for more information including program manager contact info. Submissions close June 30 at 5pm EST.

**THE NATIONAL COVID COHORT COLLABORATIVE (N3C)**: The National Center for Data to Health (CD2H) and NCATS are creating a centralized, secure portal for hosting row-level COVID-19 clinical data – the National COVID Cohort Collaborative (N3C). This initiative is a partnership between the CTSA program, several HHS agencies, and the distributed clinical data networks PCORnet, OHDSI, ACT/i2b2, and TriNetX. We believe the N3C portal will enable the rapid development of analytics that clinical centers and physicians need now. To learn more, visit [https://covid.cd2h.org/N3C](https://covid.cd2h.org/N3C)

**IN THE SPOTLIGHT**

**FREE CAPCaT Virtual Startup Showcase & Strategic Partnership Connector**: Attend this free online event to see high-potential medtech startups virtually demo their innovations. THEN, learn how to build strategic partnerships—critical to the advancement of your innovation—during a panel presentation with:

- Lana Caron, Philips HealthWorks
- Mark Boden, Boston Scientific
- Ibraheem Badejo, Johnson & Johnson Innovation Center
- John Benco, Siemens Healthcare
- Gladys Nunez, Amgen Venture Group
- Stephen Flaim, Ph.D, NIH Investor in Residence
To register visit: https://www.eventbrite.com/e/capcat-virtual-startup-showcase-strategic-partnership-connector-tickets-95020636281

**FUNDING**

**CCTS SPARK PROGRAM:** Rolling application deadline. This program’s priorities are to support studies that impact clinical care and research methodologies, support students/trainees, and provide access to funds to generate pilot and preliminary data for external grant submissions. For more information, click on this link: https://www.umassmed.edu/ccts/funding/spark-program/

**CCTS SMALL CONFERENCE GRANTS:** Rolling application deadline. This funding facilitates the development of faculty-to-faculty networks within the University system. Click on this link for more information: https://umassmed.edu/ccts/funding/small-conference-grants/

**FUNDING OPPORTUNITY:** postdoctoral fellowships to prepare the next generation of scientists to conduct implementation research that addresses critical cancer prevention and control care delivery issues.

**T32 PRACCTIS PROGRAM:** The National Cancer Institute-funded T32 PRACCTIS program (Prevention and Control of Cancer: Training for Change in Individuals and Systems) is now accepting applications for postdoctoral trainees to start August 2020. PRACCTIS is an NCI-funded training program designed to prepare the next generation of scientists to conduct implementation research that addresses critical cancer prevention and control care delivery issues across the cancer continuum, including primary prevention, cancer screening, diagnosis, treatment and survivorship.

- Trainees must be interested in pursuing a career focused on cancer prevention and control implementation research. All applicants must pursue independent research in this area.
- Eligible trainees will have with doctoral degrees (MD, DO, Ph.D., Sc.D., etc.) and a primary mentor affiliated with one of the partnering institutions. External candidates will be matched with a mentor during the interview process.
- Full applications are due by June 30, 2020.

For more information, contact barbara.estabrook@umassmed.edu and see www.umassmed.edu/pracctis

**EDUCATION**

**UMASS AMHERST SURVEY: CLINICIAN INPUT NEEDED:** Researchers from the Nolden Lab, Department of Food Science, UMass Amherst, are recruiting participants for a research study to identify areas and clinical groups which need different education and tools to help treat patients suffering from taste distortions. If you are a qualified clinician who (1) works within the US; and (2) works with patients that complain of taste problems as a result of cancer treatments, you are invited to participate in a brief online survey which will take around fifteen (15) minutes. Your participation will help to untangle disparities in taste assessing methods and terminologies, which will help identify successful and uniform taste distortion management techniques. To participate, click here or email
Upon completion of the study, you will be entered into a raffle where ten (10) $100 Amazon gift cards will be given away!

UMASS PATIENT SURVEY: WHAT’S YOUR TAKE ON THE USE OF TECHNOLOGY IN HEALTH CARE? We want your advice on which new medical technologies should be developed to help you and your healthcare provider. We value your opinion about which medical tests you believe would be most helpful. Your input is invaluable for guiding support toward products that will do the most good.

Researchers at the University of Massachusetts focused on heart, lung, blood, and sleep disorders (CAPCaT) have created a brief survey that will help inform how we support promising new technologies. This survey has 21 questions and should take about 10 minutes to complete. Participation is entirely voluntary, and you can stop at any time. Your survey responses will be anonymous. Thank you in advance for providing critical feedback to CAPCaT.

To participate click here: https://arcsapps.umassmed.edu/redcap/surveys/?s=AK3ET3RTLY

If you have any questions, please contact Nate Hafer at nathaniel.hafer@umassmed.edu.

DID YOU KNOW?

HRPP QA/QI: The Human Research Protection Program (HRPP) Quality Assurance/Quality Improvement (QA/QI) Program is a component of the UMass Center for Clinical and Translational Science. The program is independent of the IRB and helps study teams and investigators by conducting routine post-approval monitoring of on-going research to evaluate adherence with institutional requirements and federal regulations. If there are review findings, the QA/QI manager shares those findings with investigators and study teams, and provides direct education on the findings, including how to avoid making similar errors in the future. In order to support improvement at an institutional level, the QA/QI manager shares aggregated data from reviews with the HRPP leadership and the Research Community to identify trends and target areas for education. The program also makes self-evaluation tools available to investigators and study teams seeking to perform their own assessments. To learn more about HRPP QA/QI HRP-142, visit: https://www.umassmed.edu/globalassets/ccts/ccts-media/irb/updated-sops-2015/hrp-142-hrpp-qa-qi-program-final.pdf.

NATIONAL CENTER FOR DATA TO HEALTH (CD2H): The goal of CD2H is to make data more meaningful, open and accessible. The CD2H supports a vibrant and evolving collaborative informative ecosystem for the CTSA program and beyond. The CD2H harnesses and expands an ecosystem for translational scientists to discover and share their software, data and other research resources within the CTSA program network. The CD2H also creates a social coding environment for translational science institutions, leveraging the community-driven DREAM challenges as a mechanism to stimulate innovation. To learn more, click here.

SHARE YOUR SUCCESS STORY

Have you had your research published that cites the UMass Center for Clinical and Translational Science? Has your patent been filed on technology developed using Center funding or resources?
your pilot project receive external grant funding? Share it with us at ccts@umassmed.edu. Sharing your success demonstrates the importance and effect of the Center for Clinical and Translational Science at UMass.

**CITE & SUBMIT**

Please cite the NIH CTSA award any time you use The UMMS Center for Clinical and Translational Science resources, services and facilities or received funding through the Center. “The project described is supported by the National Center for Advancing Translational Sciences, National Institutes of Health, through Grant UL1 TR001453, (or TL1 TR001454, or KL2 TR001455, as appropriate). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.”

*Newsletter Submissions:* To be included in the CCTS Monthly Newsletter, please send announcements, including a link, to ccts@umassmed.edu or ellen.rupard@umassmed.edu. The newsletter is published the first week of each month.

---

University of Massachusetts Center for Clinical and Translational Science, 55 Lake Avenue N, Worcester MA 01655